Peloton Therapeutics
2011
FOUNDED
PRIVATE
STATUS
61-70
EMPLOYEES
M&A
LATEST DEAL TYPE
(Announced)
$1.05B
LATEST DEAL AMOUNT
17
INVESTORS
Description
Peloton Therapeutics Inc is a clinical stage biopharmaceutical company focused on translating novel scientific insights into medicines for patients with cancer and other debilitating or life-threatening conditions. It is focused on targeting HIF-2a, a transcription factor which was thought to be intractable using a small molecule. The company's drug candidate, PT2977, has shown clinical proof of concept in patients with advanced or metastatic clear cell renal cell carcinoma.
Website
Formerly Known As
Damascus Pharmaceuticals
Ownership Status
Privately Held (no backing)
Financing Status
Pending Transaction (M&A)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Primary Office
- 2330 Inwood Road
- Suite 226
- Dallas, TX 75235
- United States
+1 (972) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Peloton Therapeutics’s full profile, request a free trial.
Peloton Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 21-May-2019 | $1.05B | 00000 | 00.000 | Announced | Clinical Trials - Phase 2 |
| 8. IPO | 26-Apr-2019 | 00000 | 00000 | Cancelled | Clinical Trials - Phase 2 | |
| 7. Later Stage VC (Series E) | 20-Feb-2019 | 00000 | 00000 | 00000 | Completed | Generating Revenue |
| 6. Later Stage VC (Series D) | 14-Mar-2017 | 000.00 | 00000 | 00000 | Completed | Clinical Trials - Phase 2 |
| 5. Grant | 05-Aug-2016 | 0000 | 000.00 | Completed | Clinical Trials - Phase 2 | |
| 4. Later Stage VC (Series C) | 05-Nov-2014 | 000.00 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 1 |
| 3. Early Stage VC (Series B) | 18-Dec-2013 | 000.00 | 000.00 | 000.00 | Completed | Startup |
| 2. Grant | $11M | $18M | Completed | Startup | ||
| 1. Early Stage VC (Series A) | 27-Jul-2011 | $18M | $18M | 0000 | Completed | Startup |
Peloton Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | 00,000,000 | 00.000000 | 00.0 | 00.00 | 00.00 | 00 | 00.00 | 000 |
| Series D | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series C | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series B | 10,080,000 | $0.000100 | $0.1 | $1.25 | $1.25 | 1x | $1.25 | 7.68% |
| Series A | 17,100,000 | $0.000100 | $0.08 | $1 | $1 | 1x | $1 | 13.03% |
Peloton Therapeutics Competitors (22)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CEL-SCI | Corporate Backed or Acquired | Vienna, VA | 00 | 0000 | 000000000 | 0000 |
| 000000 | Venture Capital-Backed | Ann Arbor, MI | 00 | 00000 | 00000000000 | 00000 |
| 000000000 00000000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 00000000000 | 00000 |
| 00000000000 | Venture Capital-Backed | San Diego, CA | 00 | 000.00 | 00000000000 | 000.00 |
| 00000 000000000 | Corporation | Lund, Sweden | 00 | 000.00 | 000000000 | 000.00 |
Peloton Therapeutics Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| BVF Partners | Hedge Fund | Minority | 000 0000 | 000000 0 | ||
| Curative Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Driehaus Capital Management | Corporation | Minority | 000 0000 | 000000 0 | ||
| EcoR1 Capital | Hedge Fund | Minority | 000 0000 | 000000 0 | ||
| Eventide Asset Management | Asset Manager | Minority | 000 0000 | 000000 0 |
Peloton Therapeutics Executive Team (18)
2 Former Executives
You’re viewing 5 of 18 executives. Get the full list »Peloton Therapeutics Board Members (14)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Brett Ringle JD | Remeditex Ventures | Board Member | 000 0000 | |
| David Chang Ph.D | Self | Board Member | 000 0000 | |
| David Goeddel Ph.D | Self | Chairman & Member of Scientific Advisory Board | 000 0000 | |
| Helen Kim | The Column Group | Board Member | 000 0000 | |
| John Josey Ph.D | Peloton Therapeutics | President, Chief Executive Officer & Board Member | 000 0000 |
6 Former Board Members
You’re viewing 5 of 14 board members. Get the full list »